The large print giveth and the small print taketh away: Preemptive treatment of serologically active, clinically quiet systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3378-3380

  Liang, Matthew H ^a   Simard, Julia F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

AFRICAN AMERICAN; ANTIBODY TITER; ASIAN; CAUCASIAN; COMPLEMENT ACTIVATION; CORTICOSTEROID THERAPY; EDITORIAL; ETHNIC DIFFERENCE; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; DNA; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33750957994     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22199     Document Type: Editorial

References (18)

1. Tseng C, Buyon JP, Kim M, Belmont HM, MacKay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623-3 2.
2. Tseng C, Buyon J, Kim M, Belmont HM, Makay M, Diamond B, et al. Moderate dose steroids prevent severe flares in a prospective multicenter study of serologically active, clinically stable systemic lupus erythematosus (SLE) patients [abstract]. Arthritis Rheum 2003;48 Suppl 9:S260.
3. Appel AE, Sablay LB, Golden RA, Barland P, Grayzel AI, Bank N. The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study. Am J Med 1978;64:274-283.
4. Laitman RS, Glicklich D, Sabalay LB, Grayzel AI, Barland P, Bank N. Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Am J Med 1989;87:132-8.
5. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
6. Gripenberg M, Helve T. Outcome of systemic lupus erythematosus: a study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determinations. Scand J Rheumatol 1991;20:104-9.
7. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634-43.
8. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996;39:370-8.
9. Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective long term observation. Ann Rheum Dis 1997;56:661-6.
10. Hahn BH, Tsao BP. Antibodies to DNA. In: Wallace DJ, Hahn BH, Quismorio FP Jr, Klinenberg JR, editors. Dubois' lupus erythematosus. 4th ed. Philadelphia: Lea & Febiger; 1993. p. 195-201.
11. Smeenk R, Brinkman K, van den Brink H, Swaak T. A comparison of assays used for detection of antibodies to DNA. Clin Rheumatol 1990;9 Suppl 1:63-73.
12. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979;66:210-5.
13. Walz-LeBlanc BA, Gladman DD, Urowitz EM. Serologically active clinically quiescent systemic lupus erythematosus: predictors of clinical flares. J Rheumatol 1994;21:2239-41.
14. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
15. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability [review]. Arthritis Rheum 2004;50:1709-20.
16. Illei GG, Tackey L, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity [review]. Arthritis Rheum 2004;50:2048-65.
17. Liang MH, Costenbader KH, Ward M, Fortin P, Illei GG, Manzi S, et al. The validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus. In progress.
18. Fraenkel L, Bogardus S, Concato J. Patient preferences for treatment of lupus nephritis. Arthritis Rheum 2002;47:421-8.